Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 39.19M P/E - EPS this Y -67.10% Ern Qtrly Grth -
Income -10.1M Forward P/E -2.37 EPS next Y -6.10% 50D Avg Chg -10.00%
Sales 9.55M PEG - EPS past 5Y - 200D Avg Chg -11.00%
Dividend N/A Price/Book 2.43 EPS next 5Y - 52W High Chg -51.00%
Recommedations 1.70 Quick Ratio 9.56 Shares Outstanding 15.22M 52W Low Chg 7.00%
Insider Own 7.63% ROA -23.55% Shares Float 12.78M Beta -
Inst Own 21.61% ROE -41.64% Shares Shorted/Prior 173.57K/160.65K Price 3.94
Gross Margin -14.15% Profit Margin -105.71% Avg. Volume 151,533 Target Price 15.63
Oper. Margin -94.48% Earnings Date - Volume 32,590 Change -1.01%
About Coya Therapeutics, Inc.

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Coya Therapeutics, Inc. News
12/18/24 Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)
11/25/24 Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference
11/19/24 Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders
11/06/24 Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results
11/01/24 Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer
10/30/24 Coya Therapeutics Reports Positive Phase 2 Alzheimer’s Trial Results
10/29/24 Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study
10/29/24 Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer’s Disease (AD) Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid (Spain)
10/28/24 Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer’s Disease
03:05 PM Coya Therapeutics Announces Closing of $10.0 Million Private Placement
10/22/24 Coya Therapeutics Announces $10.0 Million Private Placement
10/08/24 Coya Therapeutics Chairman and CEO Howard Berman Selected for PharmaVoice 100
09/24/24 Coya Therapeutics to Participate in Fireside Chat at the Chardan 8th Annual Genetic Medicines Conference
09/16/24 Coya Therapeutics Announces Subcutaneously Administered COYA 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of Parkinson’s Disease
09/03/24 Here's Why We're Not At All Concerned With Coya Therapeutics' (NASDAQ:COYA) Cash Burn Situation
09/03/24 Coya Therapeutics to Present at Upcoming Healthcare Conferences
08/19/24 Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer Effective November 1st, 2024
08/12/24 Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results
08/02/24 Coya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer’s Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid
07/31/24 Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
COYA Chatroom

User Image irf944 Posted - 11 hours ago

$COYA Low volume today with big bid/ask spread. End of year tax selling may be wrapping up. Shares are hard to buy today. Looking forward to higher prices in near term based on chart. We are sitting at support.

User Image Paco_the_Dirty_Gringo Posted - 3 days ago

$PTIX $COYA is advancing in the tech sector, and $PTIX is advancing in the healthcare sector with its focus on CNS treatments. Both stocks offer strong growth potential in their respective industries.

User Image irf944 Posted - 4 days ago

$COYA Added. $40M Cash and a lot of data 1st quarter....low float. Will not take much to drive prices right back up. Buy target reiterated yesterday wiht $15 Target. D. Boral Capital Maintains Buy on Coya Therapeutics, Maintains $15 Price Target

User Image GolfnutBostonMass Posted - 5 days ago

$COYA ok, I joined the party

User Image Jwa68 Posted - 5 days ago

$COYA

User Image microcapspeculator Posted - 5 days ago

$COYA Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD) https://ir.coyatherapeutics.com/news/news-details/2024/Coya-Therapeutics-Provides-Enrollment-Update-of-the-Investigator-Initiated-Phase-1-Study-of-Low-Dose-Interleukin-2-LD-IL-2--CTLA4-Ig-Fusion-Protein-in-Patients-with-Frontotemporal-Dementia-FTD/default.aspx

User Image irf944 Posted - 6 days ago

$COYA Added.

User Image buffalochips62 Posted - 6 days ago

$COYA Strange. I have no price update today on 2 platforms. Has anyone traded it today?

User Image GolfnutBostonMass Posted - 6 days ago

$COYA I’m considering starting a position. They are still quite a ways out for any type of FDA approvals, correct ?

User Image Jwa68 Posted - 6 days ago

$COYA Normally I like to provide tangible evidence snd due diligence to support my convictions and there are just so many here that could be sited. Today I'm inclined to dumb it down a little. The current price just strikes me as silly.

User Image microcapspeculator Posted - 1 week ago

$COYA New December presentation on website. Roughly $40m in cash and another $8.4m in first half of year when ALS trial starts. Looks like a lot of data coming.

User Image Will2ride1 Posted - 1 week ago

$COYA back in with a starter

User Image Jwa68 Posted - 1 week ago

$COYA This is certainly interesting...The brain is Eli Lilly's next target for its obesity meds LLY interest in pursuing GLP-1 for cognitive disorders. Coya ironically has the combo IP to study obesity drugs in addiction, and is considering cognitive disorders if I'm recalling correctly. Dr. Reddy’s may want to watch out...they may not be the only one that may find Coya of interest. https://endpts.com/lilly-to-study-obesity-drugs-in-addiction-and-is-considering-cognitive-disorders/

User Image kornlover Posted - 1 week ago

$COYA So we are dead in the water until late 2025?

User Image microcapspeculator Posted - 2 weeks ago

$COYA Recent interview. Coya Therapeutics CEO Howard Berman on Advancing Neurodegenerative Therapies & Driving Innovation https://go.ivoox.com/rf/136652764

User Image TheDailyCandle Posted - 2 weeks ago

$ENTO Adding to my watchlist for a crazy move up! Massive buys and uptrend all week! Looking good for that higher move! $ENSV Had a pr in november, looks for more $THAR nice news and pop last night $COYA Any update yet?

User Image The_Platinum_Polyhedron Posted - 2 weeks ago

$THAR was a nice example of the sort of moderate spike you can see on the release of well anticipated news. $COYA is an analog for the dynamic seen when expected news delays overlong. I like that $ENTO is running on speculation about previously unexpected news. The news would have to be related to Merger or phase-3 trial, both the sort that run micro floats into triple digit ranges.

User Image Jwa68 Posted - 2 weeks ago

$COYA Highly accomplished management and board of directors, all with their own money where their mouths are and goals alligned with shareholders. Exceedingly strong balance sheet, no debt and numerous future non dilutive milestones over the next year with partner Dr. Reddy’s, who ultimately likely acquires. Risk versus reward highly compelling with reasonable downside to maybe $5 50 and conservative upside of $15. Risking 50 cents or so to possibly make $10. Great asymmetric risk. 2025 should prove positive for the company and shareholders. I continue to predict a likely exit in Q3 post forwt patient dosing in the ALS trial. If I was looking to build a position, I'd be doing it right her and now with a 12 month time horizon. Again, management is exceptional and has a ton of integrity. They always act in shareholders best interest which is rare and appreciated. Do your own dd.

User Image TheDailyCandle Posted - 2 weeks ago

$ENTO Adding to my watchlist for a crazy move up! Massive buys and uptrend all week! Loking good for that higher move! $ENSV Had a pr in november, looks for more $THAR nice news and pop last night $COYA Any update yet?

User Image GuruChartist Posted - 2 weeks ago

$COYA Added COYA to my Tax Loss Bouncer list for a January flip.

User Image EmotionlessRobot Posted - 2 weeks ago

$COYA Undervalued imo, no dilution worries and an excellent therapy.

User Image G101SPM Posted - 2 weeks ago

$COYA $6.19 ask. BUY/NEW LONG POSITION carries SPM 86.94 tag to $11.00 in midterm.

User Image irf944 Posted - 2 weeks ago

$COYA D. Boral Capital analyst Jason Kolbert initiates coverage on Coya Therapeutics (COYA.NaE) with a Buy rating and announces Price Target of $15.

User Image microcapspeculator Posted - 2 weeks ago

$COYA The 20 minute interview can be accessed through original email. Good review of what is coming for ALS and FTD trials next year. Looks like AD studies will be externally funded or partnerships. Maybe combo of both. I think they learned a lot about LD IL-2 in latest study and the higher dose usage in conjunction with CTLA4 may make sense for ALS trial that starts next year.

User Image Mulhollandr Posted - 3 weeks ago

$CLNN $BCLI $COYA $NRSN $AMLX Take a look, this video asks some interesting questions and provides unique perspective from the inventor of CNM-au8. Only posting cross boards bc I believe relevant. FYI I held decent positions (for me) in each of these stocks over the years and still hold some in all but one of them.

User Image Jwa68 Posted - 11/27/24

$COYA Deep value here.

User Image microcapspeculator Posted - 11/27/24

$COYA Don't forget to sign up if interested in next weeks call. Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer Arun Swaminathan, Ph.D. and Executive Chairman Howard Berman, Ph.D. will participate in the 7 th Annual Evercore HealthCONx Conference being held on December 3 – 5, 2024 at the Loews Coral Gables Hotel in Coral Gables, FL. On Tuesday, December 3 at 12:55 PM ET, Drs. Swaminathan and Berman will participate in a fireside chat moderated by Evercore ISI’s Director of Biotechnology and Pharmaceuticals Michael DiFiore. Drs. Swaminathan and Berman will also be available for one-on-one meetings throughout the conference. Investors can listen to the fireside chat by clicking here.

User Image microcapspeculator Posted - 11/27/24

$COYA New CEO brings strategic vision to Houston co. advancing neurodegenerative disease treatments https://houston.innovationmap.com/coya-therapeutics-arun-swaminathan-ceo-2670009696.html

User Image alphawolftrading Posted - 11/27/24

$COYA https://youtu.be/mmPvH_OOMes?si=5qS0sgeuXQ9M-LbY

User Image Robby83 Posted - 11/26/24

$COYA I still like this zone for price movement given where they're at in R&D. Might get a little quiet for the weeks to come. I fear the broader market is due for a small correction with the parabolic move upward in the past few months.

Analyst Ratings
HC Wainwright & Co. Buy Sep 16, 24
Rodman & Renshaw Buy Jun 13, 24
Chardan Capital Buy Jun 5, 24
Chardan Capital Buy May 9, 24
Chardan Capital Buy Apr 29, 24
Chardan Capital Buy Mar 20, 24
EF Hutton Buy Aug 9, 23
Chardan Capital Buy Aug 9, 23
Chardan Capital Buy Jul 18, 23